EMCN (E3Z4D) Rabbit mAb #96380
- WB
- IP
- IHC
Supporting Data
| REACTIVITY | H |
| SENSITIVITY | Endogenous |
| MW (kDa) | 95-110 |
| Source/Isotype | Rabbit IgG |
Application Key:
- WB-Western Blotting
- IP-Immunoprecipitation
- IHC-Immunohistochemistry
Species Cross-Reactivity Key:
- H-Human
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
| Immunoprecipitation | 1:50 |
| Immunohistochemistry (Paraffin) | 1:1000 - 1:4000 |
Storage
For a carrier free (BSA and azide free) version of this product see product #89278.
Protocol
Specificity / Sensitivity
EMCN (E3Z4D) Rabbit mAb recognizes endogenous levels of total EMCN protein.
Species Reactivity:
Human
Source / Purification
Monoclonal antibody is produced by immunizing animals with recombinant protein specific to the extracellular domain of human EMCN protein.
Background
Endomucin (EMCN) is a type I transmembrane O-sialoglycoprotein expressed in endothelium in venules and capillaries, but not arteries (1,2). EMCN prevents leukocyte adhesion in non-inflamed tissues, and downregulation of EMCN during inflammation facilitates migration of inflammatory cells into target tissues (3). Notch activation in endothelial cells downregulates EMCN and promotes migration of neutrophils, modulating acute inflammation in hepatic ischemia/reperfusion injury (4). EMCN deficiency in endothelial cells drives tumor lung metastasis by providing a premetastatic niche for cancer cell colonization, and is a potential prognostic biomarker for highly metastatic cancers (5). Combined analysis of EMCN/MUC15 has been suggested as a prognostic signature for gastric cancer (6).
- Kuhn, A. et al. (2002) J Invest Dermatol 119, 1388-93.
- dela Paz, N.G. and D'Amore, P.A. (2009) Cell Tissue Res 335, 5-16.
- Zahr, A. et al. (2016) Nat Commun 7, 10363.
- Zhang, P. et al. (2020) Sci China Life Sci 63, 375-387.
- Zhang, G. et al. (2022) J Transl Med 20, 446.
- Dai, W. et al. (2020) Front Mol Biosci 7, 19.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.